Navigation Links
Date Set for LightLab Damages Trial Against Volcano and Axsun

WESTFORD, Mass., Feb. 9 /PRNewswire/ -- LightLab Imaging, Inc., pioneer and leader in the development of Optical Coherence Tomography (OCT) for coronary artery applications, today reported that Trial Judge Margaret Hinkle has set March 22 for the commencement of the next phase of an ongoing trial to address damages LightLab Imaging is claiming against Volcano Corporation and its wholly owned subsidiary, Axsun Technologies, Inc.  After a four week trial that addressed only the liability claims in this litigation, a 13 person jury in the Massachusetts Superior Court rendered its liability verdict on February 4, 2010, finding:  

  • Axsun, which was acquired by Volcano in December 2008, breached its exclusive contract with LightLab Imaging
  • Axsun and Volcano misappropriated LightLab's trade secret information
  • Volcano was unjustly enriched by gaining access to LightLab's trade secret information
  • Volcano intentionally interfered both with LightLab's contract and with LightLab's advantageous business relationship with Axsun
  • Axsun breached the implied covenant of good faith and fair dealing in the LightLab contract

In addition, the jury found for LightLab in a dispute over the interpretation of LightLab's rights of exclusivity under its contract with Axsun, and found for LightLab that the contract had been modified to require Axsun to deliver a particular state-of-the-art laser to LightLab.

At a future date, LightLab will also be asking the Court to issue injunctions against Volcano and Axsun consistent with the jury's findings.  

About LightLab Imaging

LightLab Imaging, Inc., based in Westford, MA is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab currently sells its OCT systems and imaging catheters in twenty countries in Europe, Asia, the Middle East and South America. It currently does not sell products in the United States for clinical use. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patient's wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more information, and more precise information, than ever before available. For more information, visit

SOURCE LightLab Imaging, Inc.



SOURCE LightLab Imaging, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
4. Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company
5. Delcath Systems Begins Data Analysis of Phase III Trial
6. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
11. Pivotal Trial Results for Motavizumab Published in Current Issue of Pediatrics
Post Your Comments:
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The ... Dallas, TX, on January 29 and 30, 2016. The course welcomes dental professionals ... their practices, to learn how to better succeed in the modern dental marketplace. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Dr. Seth ... three office locations, patients can visit Dr. Margulies to experience the best available orthodontic ... hold the title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ”Dying Words: The ... be released on December 1, 2015, to coincide with World AIDS Day. The multi-media ... journalist who covered the AIDS epidemic as he was dying of the disease. , ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
Breaking Medicine News(10 mins):